New Zealand Research
Canterbury Respiratory Research Group - AIR (Alpha-1 Antitrypsin Deficiency International Registry) Genetics Study –This research group has faculty members with expertise in alpha1 antitrypsin deficiency: Assoc. Prof Jeff Garrett (Middlemore Hospital), Dr. Jan Stolk, and Prof. Peter George.
A survey of respiratory and sleep services in New Zealand undertaken by the Thoracic Society of Australia and New Zealand (TSANZ) by Jeff Garrett, Bob Chen, D Robin Taylor NZ Medical Journal, 13 Feb 2009, vol. 122, no. 1289.
This report revealed that there are wide variations in access to ventilation equipment and oxygen therapy across NZ.
Safety and efficacy of alpha-1 antitrypsin augmentation therapy in the treatment of patients with alpha-1 antitrypsin deficiency by I. Petrache and colleagues in Biologics (2009) vol. 3, pp. 193–204.
Augmentation therapy (IV infusion of human plasma containing functional AAT protein to correct for the deficiency) is not available in NZ but Middlemore Hospital (Auckland) has previously been included as a clinical trial site in other alpha-1 studies.
Alpha1-antitrypsin deficiency: current perspective on research, diagnosis, and management by Jan Stolk and colleagues in International Journal of COPD (2006), vol. 1, no. 2, pp. 151–60.
Prof. Stolk was a participant in the Alpha1 International Registry and collaborates with the Canterbury Respiratory Research Group in NZ.